North America Bioproduction Market Forecast to 2030

North America Bioproduction Market Forecast to 2030

North America Bioproduction Market Forecast to 2030 – Regional Analysis – by Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), and End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others)

Send Enquiry
Item ID: BMIRE00030058 Category: Tag:

$2,485 – $3,885

Description

The North America bioproduction market was valued at US$ 10,947.48 million in 2022 and is expected to reach US$ 31,373.65 million by 2030; it is estimated to register a CAGR of 14.1% from 2022 to 2030.

Rising Adoption of Regenerative Medicines Fuels North America Bioproduction Market

Regenerative therapies help in the regeneration of cells, tissues, and organs to restore their functions. A number of regenerative medicine applications for human clinical trials are submitted to the Food and Drug Administration (FDA) each year. As per the Alliance for Regenerative Medicine, in 2019 (Q3), 1,052 clinical trials utilizing regenerative medicine were underway globally; 218 cellular therapy trials were underway (41 Phase I, 147 Phase II, 30 Phase III) in 2019. Rapid advancements are being made in regenerative medicines to provide effective solutions for chronic conditions. Cell therapy is one of the fastest-growing segments of the regenerative medicine domain. Novartis’ Kymriah was the first cell therapy solution offered to treat B-cell acute leukemia. Moreover, RepliCel, a regenerative medicine provider, has a wide range of regenerative medicine products in the pipeline, with three products-RCH-01, RCS-01, and RCT-01-in the development phase. Further, Sernova is engaged in the development of regenerative medicine technologies and has a huge pipeline of products for conditions such as diabetes, hemophilia A, and hyperthyroidism. Thus, the rising adoption of regenerative medicines is driving the bioproduction market.

North America Bioproduction Market Overview

The North America bioproduction market is subsegmented into the US, Canada, and Mexico. In Mexico, the demand for cell therapy is quite noteworthy owing to growing medical tourism for stem cell therapy. The bioproduction market in North America accounted for the largest market share in 2022 due to increasing incidence of diabetes and infertility, as well as rising product developments in biosimilars.

Growing incidences of genetic and cellular disorders are leading to increasing demand for cell therapies. A 2020 PhRMA report on the cell and gene therapy pipeline revealed that there are 400 cell and gene therapies in development to target a variety of diseases and conditions from cancer to genetic disorders to neurologic conditions in the US. As of February 2020, nine cell or gene therapy products were approved in the US to treat cancer, eye diseases and rare hereditary diseases. Also, an increasing number of start-ups are innovating cell therapies in the country.

North America Bioproduction Market Revenue and Forecast to 2030 (US$ Million)

North America Bioproduction Market Segmentation

The North America bioproduction market is categorized into product, application, equipment, end user, and country.

Based on product, the North America bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held the largest North America bioproduction market share in 2022.

In terms of application, the North America bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held the largest North America bioproduction market share in 2022.

By equipment, the North America bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held the largest North America bioproduction market share in 2022.

In terms of end user, the North America bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held the largest North America bioproduction market share in 2022.

By country, the North America bioproduction market is segmented into the US, Canada, and Mexico. The US dominated the North America bioproduction market share in 2022.

Bio-Rad Laboratories Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, Lonza Group AG, Merck KGaA, Sartorius AG, and Thermo Fisher Scientific Inc. are some of the leading companies operating in the North America bioproduction market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication:

At 14.1% CAGR, North America Bioproduction Market is Speculated to be Worth US$ 31,373.65 Million by 2030, says the Research Team

According to the Research Team’ research, the North America bioproduction market was valued at US$ 10,947.48 million in 2022 and is expected to reach US$ 31,373.65 million by 2030, registering a CAGR of 14.1% from 2022 to 2030. Shift toward automated cell therapy manufacturing and increasing prevalence of chronic diseases are among the critical factors attributed to drive the North America bioproduction market growth.

Automation can deliver many benefits for cell therapy developers, including reduced risk of contamination, improved consistency, and reduced cost of production. Many companies have offered devices to enable automation, such as the Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are designed to enable the automation of most sequential unit operations for a CAR-T process within a single system. A rising number of cell therapies have shifted the production of cell therapy products from a small volume to a large volume worldwide. In addition, the evolution of cell therapy, from an academic and clinical setting to mass production and commercialization, is increasing the demand for automation in manufacturing. Increasing research activities in cell therapies have led to a rise in demand for advanced manufacturing solutions. In view of this, many players are offering products to meet the digital needs of academic researchers and large biotechnology companies. For instance, in May 2019, GE Healthcare launched the Chronicle web application to support the complete cell therapy workflow. Chronicle automation software is a good manufacturing practice (GMP)-compliant digital solution designed to optimize complex cell therapy process development and manufacturing.

Companies are also entering into strategic and technological developments for automation in cell therapy. For instance, in July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the fitness of T-cells and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software) along with reagents, consumables, and instruments. Thus, the increasing adoption of automation among cell therapy manufacturers is anticipated to drive the market.

On the contrary, high cost of cell therapy and biosimilar manufacturing hampers the growth of North America bioproduction market.

Based on product, the North America bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held 39.4% North America bioproduction market share in 2022, amassing US$ 4,308.08 million. It is projected to garner US$ 11,594.72 million by 2030 to register 13.2% CAGR during 2022-2030.

In terms of application, the North America bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held 36.0% share of North America bioproduction market in 2022, amassing US$ 3,944.62 million. It is anticipated to garner US$ 11,778.97 million by 2030 to expand at 14.7% CAGR during 2022-2030.

By equipment, the North America bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held 39.6% share of North America bioproduction market in 2022, amassing US$ 4,336.79 million. It is projected to garner US$ 13,131.32 million by 2030 to expand at 14.9% CAGR from 2022 to 2030.

In terms of end user, the North America bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held 51.7% share of North America bioproduction market in 2022, amassing US$ 5,664.04 million. It is projected to garner US$ 16,054.41 million by 2030 to expand at 13.9% CAGR from 2022 to 2030.

Based on country, the North America bioproduction market is categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 90.3% share of North America bioproduction market in 2022. It was assessed at US$ 9,888.86 million in 2022 and is likely to hit US$ 28,892.00 million by 2030, registering a CAGR of 14.3% during 2022-2030.

Key players operating in the North America bioproduction market are Bio-Rad Laboratories Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, Lonza Group AG, Merck KGaA, Sartorius AG, and Thermo Fisher Scientific Inc., among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America bioproduction market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the North America bioproduction market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America bioproduction market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Bioproduction Market – Key Industry Dynamics
4.1 Market Drivers
4.1.1 Rising Adoption of Regenerative Medicines
4.1.2 Increasing Prevalence of Chronic Diseases
4.2 Market Restraints
4.2.1 High Cost of Cell Therapy and Biosimilar Manufacturing
4.3 Market Opportunities
4.3.1 Patent Expiry of Blockbuster Biologics
4.4 Future Trends
4.4.1 Shift Toward Automated Cell Therapy Manufacturing
4.5 Impact Analysis
5. Bioproduction Market – North America Market Analysis
5.1 North America Bioproduction Market Revenue (US$ Mn), 2020 – 2030
6. North America Bioproduction Market – Revenue and Forecast to 2030 – by Product
6.1 Overview
6.2 North America Bioproduction Market Revenue Share, by Product 2022 & 2030 (%)
6.3 Biologics and Biosimilars
6.3.1 Overview
6.3.2 Biologics and Biosimilars: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Cell and Gene Therapies
6.5.1 Overview
6.5.2 Cell and Gene Therapies: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Nucleic Acid Therapeutics
6.6.1 Overview
6.6.2 Nucleic Acid Therapeutics: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.7 Others
6.7.1 Overview
6.7.2 Others: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7. North America Bioproduction Market – Revenue and Forecast to 2030 – by Application
7.1 Overview
7.2 North America Bioproduction Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Cardiovascular Diseases
7.4.1 Overview
7.4.2 Cardiovascular Diseases: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Rheumatoid Arthritis
7.5.1 Overview
7.5.2 Rheumatoid Arthritis: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Hematological Disorders
7.6.1 Overview
7.6.2 Hematological Disorders: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Diabetes
7.7.1 Overview
7.7.2 Diabetes: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Others
7.8.1 Overview
7.8.2 Others: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Bioproduction Market – Revenue and Forecast to 2030 – by Equipment
8.1 Overview
8.2 North America Bioproduction Market Revenue Share, by Equipment 2022 & 2030 (%)
8.3 Consumables and Accessories
8.3.1 Overview
8.3.2 Consumables and Accessories: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Downstream Equipment
8.4.1 Overview
8.4.2 Downstream Equipment: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Bioreactors
8.5.1 Overview
8.5.2 Bioreactors: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8.5.2.1 North America: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
8.6 Upstream Equipment
8.6.1 Overview
8.6.2 Upstream Equipment: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Bioproduction Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 North America Bioproduction Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Biopharmaceutical Companies
9.3.1 Overview
9.3.2 Biopharmaceutical Companies: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Contract Manufacturing Organizations
9.4.1 Overview
9.4.2 Contract Manufacturing Organizations: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Bioproduction Market – Revenue and Forecast to 2030 – Country Analysis
10.1 North America: Bioproduction Market
10.1.1 US: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1 Overview
10.1.1.2 US: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3 US: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.4 US: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.5 US: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.5.1 US: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.6 US: Bioproduction Market, by End User, 2020-2030 (US$ Million)
10.1.1.2 Canada: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Canada: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.3 Canada: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.2.4 Canada: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.2.5 Canada: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.2.5.1 Canada: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.2.6 Canada: Bioproduction Market, by End User, 2020-2030 (US$ Million)
10.1.1.3 Mexico: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 Mexico: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.3 Mexico: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.3.4 Mexico: Bioproduction Market, by Application, 2020-2030 (US$ Million)
10.1.1.3.5 Mexico: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
10.1.1.3.5.1 Mexico: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.3.6 Mexico: Bioproduction Market, by End User, 2020-2030 (US$ Million)
11. Bioproduction Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Bioproduction Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Lonza Group AG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Danaher Corp
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Sartorius AG
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Thermo Fisher Scientific Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Merck KGaA
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 F. Hoffmann-La Roche Ltd
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Bio-Rad Laboratories Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

LIST OF TABLES

Table 1. North America Bioproduction Market Segmentation
Table 2. North America Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 3. US Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 4. US Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. US Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 6. US Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 7. US Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 13. Mexico Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico Bioproduction Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Bioproduction Market, by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Bioproduction Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 18. Recent Inorganic Growth Strategies in the Bioproduction Market
Table 19. Recent Organic Growth Strategies in the Bioproduction Market
Table 20. Glossary of Terms, Bioproduction Market
 

LIST OF FIGURES

Figure 1. North America Bioproduction Market Segmentation, By Country
Figure 2. North America Bioproduction Market: Key Industry Dynamics
Figure 3. North America Bioproduction Market: Impact Analysis of Drivers and Restraints
Figure 4. North America Bioproduction Market Revenue (US$ Mn), 2020 – 2030
Figure 5. North America Bioproduction Market Revenue Share, by Product 2022 & 2030 (%)
Figure 6. Biologics and Biosimilars: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Vaccines: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Cell and Gene Therapies: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Nucleic Acid Therapeutics: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Others: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. North America Bioproduction Market Revenue Share, by Application 2022 & 2030 (%)
Figure 12. Cancer: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Cardiovascular Diseases: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Rheumatoid Arthritis: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Hematological Disorders: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Diabetes: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Bioproduction Market Revenue Share, by Equipment 2022 & 2030 (%)
Figure 19. Consumables and Accessories: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Downstream Equipment: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Bioreactors: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Upstream Equipment: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. North America Bioproduction Market Revenue Share, by End User 2022 & 2030 (%)
Figure 24. Biopharmaceutical Companies: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Contract Manufacturing Organizations: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Others: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. North America: Bioproduction Market, by Key Country – Revenue (2022) (US$ Million)
Figure 28. North America: Bioproduction Market, by Country, 2022 & 2030 (%)
Figure 29. US: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. Canada: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. Mexico: North America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Growth Strategies in the Bioproduction Market

1. Bio-Rad Laboratories Inc
2. Danaher Corp
3. F. Hoffmann-La Roche Ltd
4. Lonza Group AG
5. Merck KGaA
6. Sartorius AG
7. Thermo Fisher Scientific Inc

Reviews

There are no reviews yet.

Be the first to review “North America Bioproduction Market Forecast to 2030”